Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

被引:499
|
作者
Ogitani, Yusuke [1 ]
Hagihara, Katsunobu [2 ]
Oitate, Masataka [2 ]
Naito, Hiroyuki [3 ]
Agatsuma, Toshinori [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Biol & Immunooncol Labs, Tokyo, Japan
[2] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Tokyo, Japan
[3] Daiichi Sankyo Co Ltd, Oncol Labs, Tokyo, Japan
关键词
Antibody-drug conjugate; bystander killing; HER2; T-DM; topoisomerase I inhibitor; BRENTUXIMAB VEDOTIN; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; CATHEPSIN-B; EXPRESSION; LYMPHOMA; THERAPY; PHASE-3; SAFETY;
D O I
10.1111/cas.12966
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window. DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepared using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan derivative (DX-8951 derivative, DXd). It was effective against trastuzumab emtansine (T-DM1)-insensitive patient-derived xenograft models with both high and low HER2 expression. In this study, the bystander killing effect of DS-8201a was evaluated and compared with that of T-DM1. We confirmed that the payload of DS-8201a, DXd (1), was highly membrane-permeable whereas that of T-DM1, Lys-SMCC-DM1, had a low level of permeability. Under a coculture condition of HER2-positive KPL-4 cells and negative MDA-MB-468 cells in vitro, DS-8201a killed both cells, whereas T-DM1 and an antibody-drug conjugate with a low permeable payload, anti-HER2-DXd (2), did not. In vivo evaluation was carried out using mice inoculated with a mixture of HER2-positive NCI-N87 cells and HER2-negative MDA-MB-468-Luc cells by using an in vivo imaging system. In vivo, DS-8201a reduced the luciferase signal of the mice, indicating suppression of the MDA-MB-468-Luc population; however, T-DM1 and anti-HER2-DXd (2) did not. Furthermore, it was confirmed that DS-8201a was not effective against MDA-MB-468-Luc tumors inoculated at the opposite side of the NCI-N87 tumor, suggesting that the bystander killing effect of DS-8201a is observed only in cells neighboring HER2-positive cells, indicating low concern in terms of systemic toxicity. These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1.
引用
收藏
页码:1039 / 1046
页数:8
相关论文
共 50 条
  • [31] Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer
    Zardavas, Dimitrios
    Bozovic-Spasojevic, Ivana
    De Azambuja, Evandro
    CURRENT OPINION IN ONCOLOGY, 2012, 24 (06) : 612 - 622
  • [32] Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections*
    Lee, Stephen
    de Boer, Willem Bastiaan
    Fermoyle, Soraya
    Platten, Michael
    Kumarasinghe, Marian Priyanthi
    HISTOPATHOLOGY, 2011, 59 (05) : 832 - 840
  • [33] Human epidermal growth factor receptor 2, epidermal growth factor receptor, and c-MET overexpression and survival in biliary tract cancer: A meta-analysis
    Zhou, Wei
    Jiang, Congqing
    Zhan, Nan
    Lv, Xiaoguang
    Fan, Lifang
    Ninu, Maskey
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S28 - S35
  • [34] The expression of epidermal growth factor receptor 1 and human epidermal growth factor receptor 2 based on tumor location affect survival in gastric cancer
    Li, Guo-Cai
    Jia, Xu-Chun
    Zhao, Qing-Chuan
    Zhang, Hong-Wei
    Yang, Peng
    Xu, Long-Long
    Pang, Fang-Ning
    Sun, Jian-Bing
    MEDICINE, 2020, 99 (21) : E20460
  • [35] Epidermal growth factor receptor function in the human urothelium
    Wasen, C.
    Ekstrand, M.
    Levin, M.
    Giglio, D.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2018, 50 (04) : 647 - 656
  • [36] Superior Antitumor Activity of a Novel Bispecific Antibody Cotargeting Human Epidermal Growth Factor Receptor 2 and Type I Insulin-like Growth Factor Receptor
    Chen, Chao
    Zhang, Yanyu
    Zhang, Yu
    Li, Jingjing
    Tsao, Sai Wah
    Zhang, Mei-Yun
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (01) : 90 - 100
  • [37] Human epidermal growth factor receptor-2 in oesophageal cancers: An observational study
    Al-Momani, Hazem
    Barnes, Rachel
    El-Hadi, Ahmed
    Shah, Rachit
    Lewis, Wyn G.
    Edwards, Paul
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (44) : 6447 - 6451
  • [38] Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
    Sauter, Guido
    Lee, James
    Bartlett, John M. S.
    Slamon, Dennis J.
    Press, Michael F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1323 - 1333
  • [39] Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer
    Ito, Kimihiro
    Mitsunaga, Makoto
    Nishimura, Takashi
    Saruta, Masayuki
    Iwamoto, Takeo
    Kobayashi, Hisataka
    Tajiri, Hisao
    BIOCONJUGATE CHEMISTRY, 2017, 28 (05) : 1458 - 1469
  • [40] MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab plus Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors
    Sweeney, Christopher J.
    Hainsworth, John D.
    Bose, Ron
    Burris, Howard A.
    Kurzrock, Razelle
    Swanton, Charles
    Friedman, Claire F.
    Spigel, David R.
    Szado, Tania
    Schulze, Katja
    Price, Richard
    Malato, Julia
    Lo, Amy A.
    Levy, Jonathan
    Wang, Yong
    Yu, Wei
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (03) : 258 - 265